BEAM-302
Alpha-1 Antitrypsin Deficiency (AATD)
PreclinicalIND-enabling
Key Facts
Indication
Alpha-1 Antitrypsin Deficiency (AATD)
Phase
Preclinical
Status
IND-enabling
Company
About Beam Therapeutics
Beam Therapeutics is a clinical-stage biotechnology company developing a new class of precision genetic medicines based on its foundational base editing technology. The company's approach allows for the correction of point mutations, insertion or deletion of single bases, and modulation of gene expression with high efficiency and specificity. Beam is advancing a diversified pipeline of in vivo and ex vivo programs targeting sickle cell disease, alpha-1 antitrypsin deficiency, glycogen storage disease 1a, and various cancers. The company has established strategic collaborations with leading pharmaceutical partners and went public in February 2020.
View full company profileTherapeutic Areas
Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs
| Drug | Company | Phase |
|---|---|---|
| WVE-006 | WaVe Life Sciences | Phase 1/2 |
| INBRX-101 | Inhibrx Biosciences | Phase 2 |
| Glassia® (IV AAT) | Kamada | Approved |
| Inhaled AAT (KMA-001) | Kamada | Phase 3 |
| GalNAc Program (SERPINA1 target) | Korro Bio | Discovery |
| Unnamed AATD Program | AlveoGene | Pre-clinical |